세툭시맙 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "세툭시맙" in Korean language version.

refsWebsite

Global rank Korean rank

8nih.gov

4^th place

7doi.org

2^nd place

3^rd place

4web.archive.org

1^st place

2fda.gov

447^th place

433^rd place

2yedarnd.com

low place

1europa.eu

68^th place

145^th place

1health.kr

low place

2,285^th place

1escholarship.org

1,523^rd place

1,668^th place

1semanticscholar.org

11^th place

310^th place

1espacenet.com

800^th place

1,296^th place

1uscourts.gov

2,275^th place

low place

1legalmetric.com

low place

1usatoday.com

41^st place

210^th place

doi.org

dx.doi.org

Messersmith WA, Ahnen DJ (October 2008). “Targeting EGFR in colorectal cancer”. 《The New England Journal of Medicine》 359 (17): 1834–1836. doi:10.1056/NEJMe0806778. PMID 18946069.
Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). “Angiogenesis in cutaneous disease: part I”. 《Journal of the American Academy of Dermatology》 61 (6): 921–42; quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, 외. (April 2009). “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer”. 《The New England Journal of Medicine》 360 (14): 1408–1417. doi:10.1056/NEJMoa0805019. PMID 19339720.
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, 외. (July 2012). “Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials”. 《European Journal of Cancer》 48 (10): 1466–1475. doi:10.1016/j.ejca.2012.02.057. PMID 22446022.
Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (December 1988). “Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice”. 《Journal of the National Cancer Institute》 80 (20): 1605–1611. doi:10.1093/jnci/80.20.1605. PMID 3193478.
Li K, Li J (2016). “Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application”. 《Gastroenterology Research and Practice》 2016: 4105615. doi:10.1155/2016/4105615. PMC 4736909. PMID 26880889.
Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, 외. (March 2020). “Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial”. 《The Lancet. Oncology》 21 (3): 398–411. doi:10.1016/S1470-2045(19)30798-3. PMC 7052737. PMID 32014119.

escholarship.org

Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). “Angiogenesis in cutaneous disease: part I”. 《Journal of the American Academy of Dermatology》 61 (6): 921–42; quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.

espacenet.com

worldwide.espacenet.com

US patent 6217866, Sela M, Pirak E, Hurwitz E, "Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same", published 2001-04-17, assigned to Yeda Research & Development

europa.eu

ema.europa.eu

“Erbitux EPAR”. 《European Medicines Agency》. 2018년 9월 17일. 2022년 6월 2일에 확인함.

fda.gov

“Class Labeling Changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations”. U.S. Food and Drug Administration (FDA). 2010년 1월 11일.
“Therascreen KRAS RGQ PCR Kit – P110030”. 《Device Approvals and Clearances》. U.S. Food and Drug Administration (FDA). 2012년 7월 6일.

health.kr

“약학정보원”. 2023년 10월 7일에 확인함.

legalmetric.com

“Yeda Research v. Imclone Systems, et al”. 2015년 11월 20일에 원본 문서에서 보존된 문서. 2015년 8월 30일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Messersmith WA, Ahnen DJ (October 2008). “Targeting EGFR in colorectal cancer”. 《The New England Journal of Medicine》 359 (17): 1834–1836. doi:10.1056/NEJMe0806778. PMID 18946069.
Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). “Angiogenesis in cutaneous disease: part I”. 《Journal of the American Academy of Dermatology》 61 (6): 921–42; quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, 외. (April 2009). “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer”. 《The New England Journal of Medicine》 360 (14): 1408–1417. doi:10.1056/NEJMoa0805019. PMID 19339720.
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, 외. (July 2012). “Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials”. 《European Journal of Cancer》 48 (10): 1466–1475. doi:10.1016/j.ejca.2012.02.057. PMID 22446022.
Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (December 1988). “Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice”. 《Journal of the National Cancer Institute》 80 (20): 1605–1611. doi:10.1093/jnci/80.20.1605. PMID 3193478.
Li K, Li J (2016). “Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application”. 《Gastroenterology Research and Practice》 2016: 4105615. doi:10.1155/2016/4105615. PMC 4736909. PMID 26880889.
Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, 외. (March 2020). “Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial”. 《The Lancet. Oncology》 21 (3): 398–411. doi:10.1016/S1470-2045(19)30798-3. PMC 7052737. PMID 32014119.

dailymed.nlm.nih.gov

“Erbitux- cetuximab solution”. 《DailyMed》. 2021년 9월 27일. 2022년 6월 2일에 확인함.

semanticscholar.org

api.semanticscholar.org

Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). “Angiogenesis in cutaneous disease: part I”. 《Journal of the American Academy of Dermatology》 61 (6): 921–42; quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.

usatoday.com

“ImClone goes up against patent dispute”. 《USA Today》. 2006년 9월 14일.

uscourts.gov

nysd.uscourts.gov

“Court ruling on Yeda vs Aventis/Imclone case” (PDF). 2011년 9월 27일에 원본 문서 (PDF)에서 보존된 문서. 2012년 5월 25일에 확인함.

web.archive.org

“Yeda Research and Development Company Ltd”. 2016년 12월 4일에 원본 문서에서 보존된 문서. 2013년 1월 5일에 확인함. Technology Transfer Company of the Weizmann Institute of Science
Groombridge N, Gearing BP (February 2008). “Practical lessons from a "made for TV" patent litigation: The trial of Yeda Research & Development Co. Ltd. v. ImClone Systems Inc. and Aventis Pharmaceuticals Inc.” (PDF). 《The Federal Lawyer》: 51–55. 2009년 9월 3일에 원본 문서 (PDF)에서 보존된 문서.
“Court ruling on Yeda vs Aventis/Imclone case” (PDF). 2011년 9월 27일에 원본 문서 (PDF)에서 보존된 문서. 2012년 5월 25일에 확인함.
“Yeda Research v. Imclone Systems, et al”. 2015년 11월 20일에 원본 문서에서 보존된 문서. 2015년 8월 30일에 확인함.

yedarnd.com

“Yeda Research and Development Company Ltd”. 2016년 12월 4일에 원본 문서에서 보존된 문서. 2013년 1월 5일에 확인함. Technology Transfer Company of the Weizmann Institute of Science
Groombridge N, Gearing BP (February 2008). “Practical lessons from a "made for TV" patent litigation: The trial of Yeda Research & Development Co. Ltd. v. ImClone Systems Inc. and Aventis Pharmaceuticals Inc.” (PDF). 《The Federal Lawyer》: 51–55. 2009년 9월 3일에 원본 문서 (PDF)에서 보존된 문서.